Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Colorcon
Mallinckrodt
Moodys
AstraZeneca

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

FERRING Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for FERRING
International Patents:308
US Patents:23
Tradenames:17
Ingredients:8
NDAs:17
Patent Litigation for FERRING: See patent lawsuits for FERRING

Drugs and US Patents for FERRING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring Pharms Inc DDAVP desmopressin acetate SPRAY, METERED;NASAL 017922-002 Feb 6, 1989 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Ferring THYREL TRH protirelin INJECTABLE;INJECTION 018087-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
Ferring DESMOPRESSIN ACETATE desmopressin acetate TABLET;ORAL 021795-001 May 8, 2008 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FERRING

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ferring Pharms Inc DDAVP desmopressin acetate TABLET;ORAL 019955-001 Sep 6, 1995 5,763,407 ⤷  Free Forever Trial
Ferring Pharms Inc DDAVP desmopressin acetate TABLET;ORAL 019955-001 Sep 6, 1995 5,047,398 ⤷  Free Forever Trial
Ferring Pharms Inc DDAVP desmopressin acetate TABLET;ORAL 019955-002 Sep 6, 1995 5,763,407 ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for FERRING drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 10 mg, 3.5 g, and 12 g ➤ Subscribe 2014-05-21
➤ Subscribe Oral Solution 10 mg, 3.5 g, and12 g ➤ Subscribe 2019-02-11

Supplementary Protection Certificates for FERRING Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1003774 PA2009005 Lithuania ⤷  Free Forever Trial PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
2712622 PA2017001,C2712622 Lithuania ⤷  Free Forever Trial PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008
1003774 PA2009005,C1003774 Lithuania ⤷  Free Forever Trial PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Dow
Baxter
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.